---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-029355"
form_type: "8-K"
ticker: "FENC"
cik: "0001211583"
company_name: "FENNEC PHARMACEUTICALS INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:13:04.640228+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fennec prelim Q4 2023 net revenue $9.2-9.7M (+41-49% QoQ); FY 2023 $20.7-21.2M

## Summary
- Q4 2023 net revenue expected $9.2-9.7M, up 41-49% from Q3 2023.
- Full-year 2023 net revenue expected $20.7-21.2M.
- Audited Q4 and full-year results expected on or about March 26, 2024.
- PEDMARK is first FDA-approved therapy to reduce ototoxicity risk in pediatric cisplatin patients.

## SEC filing metadata
- accession: 0001104659-24-029355
- form_type: 8-K
- ticker: FENC
- cik: 0001211583
- company_name: FENNEC PHARMACEUTICALS INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/0001104659-24-029355-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1211583/000110465924029355/tm247601d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-029355
- JSON: https://secwatch.observer/filing/0001104659-24-029355.json
- Plain text: https://secwatch.observer/filing/0001104659-24-029355.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.